News OliX Pharmaceuticals, Inc

Equities

A226950

KR7226950004

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
15,200 ^KRW	+3.33%		-0.65%	+4.25%

22/03	OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors	CI
20/03	OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors	22/03	CI
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors	20/03	CI
OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug	22/12	CI
OliX Pharmaceuticals, Inc announced that it has received KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.	15/12	CI
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.	07/12	CI
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration	29/11	CI
OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia	13/23/13	CI
OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment	11/23/11	CI
OliX Pharmaceuticals, Inc Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA At Korea-US Digital BioHealth Business Forum	10/23/10	CI
OliX Pharmaceuticals, Inc Announces Positive Results from A Phase 2A Trial of Olx10010 for Hypertrophic Scar Treatment	28/23/28	CI
Olix Pharmaceuticals, Inc. Doses First Patient in Clinical Trial for Rnai Therapeutic Olx10212 for Dry and Wet Age-Related Macular Degeneration	27/23/27	CI
OliX Pharmaceuticals, Inc. Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia	23/23/23	CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.	12/22/12	CI
OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C's Potential as an Effective Treatment for Hair Loss	23/22/23	AQ
Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss	22/22/22	CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.	11/22/11	CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.	11/22/11	CI
OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration	03/22/03	CI
OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial	01/22/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OliX Pharmaceuticals, Inc

Equities

A226950

KR7226950004

Summary

Filters